Table 1.

Approved systemic therapies.

Class	Drug	Response rate %	Median DoR	Major toxicities
Immunomodulatory	Extracorporeal photopheresis (6)	5	Not well-defined	Fluid shifts, hypotension, infection, anemia
Antimetabolite	Methotrexate (7)	33	15 months	mucositis, myelosuppression, hepatic, renal toxicity
Retinoid	Bexarotene (8)	45-55	10–13 months	hyperlipemia, hypercholesterolemia hypothyroidism
HDAC inhibitor	Vorinostat (9)	30	6 months	fatigue, diarrhea, nausea, thrombocytopenia, anorexia, taste abnormalities, weight loss, and muscle spasms
HDAC inhibitor	Romidepsin (10, 11)	34	13.7–15 months	nausea vomiting, fatigue, myelosuppression, QT interval changes
IL-2 Fusion Protein	Denileukin diftitox (12)	44	7.8 months	nausea, pyrexia, fatigue, rash, LFT abnormalities, vision changes, and capillary leak syndrome
Antibody-Drug conjugate	Brentuximab vedotin (13)	56	15.1 months	peripheral neuropathy, GI upset (nausea, diarrhea, vomiting), alopecia, pruritus, pyrexia, decreased appetite, and fatigue
Monoclonal antibody	Mogamulizumab (14)	28	15.5–25.5 months	infusion-related reactions, drug rash, diarrhea, and fatigue